摘要
血管内皮生长因子抑制剂(VEGFR)广泛用于恶性肿瘤晚期治疗。高血压、血栓事件、心脏毒性是VEGFR最为常见的心血管不良事件。研究显示,降低体内NO和前列腺素的释放;损伤血管内皮,激活凝血因子;“靶向”与“脱靶”作用是引起此类心血管事件的主要机制。中医药除了有抗肿瘤的作用外,也能减轻肿瘤治疗中的心血管不良事件。该文就抗血管生成靶向药物的主要心血管事件机制及相应的中医药治疗进行整理。
Vascular endothelial growth factor inhibitors(VEGFR) are widely used in the treatment of advanced malignant tumors. Hypertension, thrombotic events, and cardiotoxicity are the most common cardiovascular adverse events of VEGFR. Studies have shown that reducing the release of NO and prostaglandins in the body;damaging the vascular endothelium and activating coagulation factors;“target” and “off-target” effects are the main mechanisms that cause such cardiovascular events. In addition to anti-tumor effects, traditional Chinese medicine can also reduce adverse cardiovascular events in tumor treatment. This article sorts out the main cardiovascular event mechanisms of antiangiogenic targeted drugs and the corresponding traditional Chinese medicine treatments.
作者
徐佳悦
郑岚
郭元彪
陈敬贤
XU Jiayue;ZHENG Lan;GUO Yuanbiao;CHEN Jingxian(Ruijin Hospital,Shanghai Jiaotong University Medical School,Shanghai 200025,China)
出处
《中医药临床杂志》
2022年第12期2393-2396,共4页
Clinical Journal of Traditional Chinese Medicine
基金
上海市科委项目心康饮联合索他洛尔治疗气阴两虚型非瓣膜性阵发性房颤的前瞻性随机对照临床研究(19401971100)。
关键词
血管内皮生长因子抑制剂
高血压
血栓事件
心脏毒性
Vascular endothelial growth factor inhibitor
Hypertension
Thrombotic events
Cardiotoxicity
Traditional Chinese medicine
